CD8A and neoplasm: Clinical response to PD-L1 inhibitors in patients with metastatic UC is associated with a CD8+ immune phenotype in the tumour cells, whilst lack of response is associated with presence of CD8+ immune cells in the fibroblast-rich peritumoural stroma, excluded from tumour cells [14].